Orthofix Medical (NASDAQ:OFIX) Given “Market Perform” Rating at JMP Securities

Orthofix Medical (NASDAQ:OFIX)‘s stock had its “market perform” rating reiterated by research analysts at JMP Securities in a research note issued to investors on Monday, Benzinga reports.

Several other research analysts have also commented on the company. Roth Mkm raised their price objective on Orthofix Medical from $12.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, March 7th. StockNews.com lowered Orthofix Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $15.50.

Orthofix Medical Trading Up 1.1 %

Shares of OFIX opened at $13.22 on Monday. The company has a current ratio of 2.54, a quick ratio of 1.20 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $494.56 million, a P/E ratio of -3.19 and a beta of 1.04. The stock’s fifty day simple moving average is $13.72 and its 200 day simple moving average is $12.91. Orthofix Medical has a twelve month low of $9.57 and a twelve month high of $21.60.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Tuesday, March 5th. The medical device company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.01. Orthofix Medical had a negative return on equity of 10.63% and a negative net margin of 20.28%. The business had revenue of $200.42 million for the quarter. On average, equities research analysts forecast that Orthofix Medical will post -1.51 earnings per share for the current year.

Institutional Trading of Orthofix Medical

A number of hedge funds and other institutional investors have recently modified their holdings of OFIX. Gladius Capital Management LP increased its position in shares of Orthofix Medical by 55.2% during the fourth quarter. Gladius Capital Management LP now owns 2,841 shares of the medical device company’s stock worth $38,000 after acquiring an additional 1,010 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Orthofix Medical by 30.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company’s stock worth $101,000 after acquiring an additional 1,752 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in shares of Orthofix Medical during the third quarter worth about $130,000. Teza Capital Management LLC purchased a new stake in shares of Orthofix Medical during the third quarter worth about $133,000. Finally, Arizona State Retirement System purchased a new stake in shares of Orthofix Medical during the fourth quarter worth about $138,000. 89.76% of the stock is owned by hedge funds and other institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.